重组促红细胞生成素治疗肾性贫血的疗效观察  

Clinical Effect of Recombinant Human Erythropoietin on Anemia of Chronic Renal Failure

作　　者：朱斌[1] 刘子栋[1] 王璞[1] 靖永胜[1] 马天旻[1] 

机构地区：[1]济南市中心医院

出　　处：《山东医药》1999年第5期5-6,共2页Shandong Medical Journal

摘　　要：观察７０例慢性肾功能衰竭合并肾性贫血患者，分别使用常规治疗方法、国产重组促红细胞生成素（ｒＨｕＥＰＯ）依普定和日本产利血宝治疗，并观察治疗前后血红蛋白（ＨＧＢ）、红细胞（ＲＢＣ）计数、红细胞压积（ＨＣＴ）、网织红细胞（ＲＣ）、白细胞（ＷＢＣ）及血小板（ＰＬＴ）计数变化及其并发症。结果：常规治疗方法（单纯肾替代治疗）不能改善慢性肾功能不全患者的贫血状态，而依普定和利血宝组则均可有效地改善贫血状态，提高生活质量，且副作用少，使用安全。Changes of hemoglobin(HGB),red blood cell(RBC)count,hemotocrit(HCT),reticulocyte(RC),white blood cell(WBC)count,platlet(PLT)count and complications were observed in 70 cases of anemia of chronic renal failure who had been treated respectively with regular treatment(single renal replacement therapy),Yi Pu Ding(rHuEPO,made in China)and ESPO(rHuEPO,made in Japan) Result showed Yi Pu Ding and ESPO can improve the patients conditions of anemia and living qualities effectively,but regular treatment can’t With less adverse effect,Yi Pu Ding and ESPO can be used safely,there are no significant difference of therapy effect and adverse rate in the two groups

关 键 词：肾性贫血 贫血 药物疗法 RHUEPO 

分 类 号：R556.05[医药卫生—血液循环系统疾病] R692.06[医药卫生—内科学]